BRONCHODILATORS → LONG-ACTING MUSCARINIC ANTAGONIST (LAMA) → Seebri®

Seebri®

BRONCHODILATORS

LONG-ACTING MUSCARINIC ANTAGONIST (LAMA)

  • Class

    • Long-acting muscarinic antagonist (LAMA)

  • Active ingredient

    • Glycopyrronium (as bromide)

  • Device

  • Age

    • 18 +

  • Typical use

    • Asthma (off-label)
      in addition to a high dose ICS + LABA when uncontrolled

    Asthma management principles

    • COPD
      initial treatment or in addition to a LABA when uncontrolled 

    COPD management principles

  • Marketed strength

    • 50 mcg

  • Number of doses

    • 30 capsules

  • Dose indicator

    • Yes | Number of capsules

  • Usual adult dosage

    • 1 inh QD

  • Usual pediatric dosage

    • -

  • Required inspiratory flow

    • > 50 L/min
      Low internal resistance (R1)

    Inspiratory flows

  • Public coverage

    • AB – MN – NIHB – ON – QC – YT | Open/Regular Benefit
      BC – NB –NL – NS – PEI – SK | Restricted Benefit with criteria 

    Provincial coverage criteria

  • Advantages

    • Low internal resistance (less effort required for inhalation)
    • Clear capsule which ensures complete inhalation

  • Disadvantages

    • Capsule handling required
    • The capsule may get stuck while rotating during inhalation
    • Cough when inhaling too quickly
    • Capsule may be ingested
    Side effects

Product monograph

Download

Tudorza®

Genuair®

Spiriva®

Handihaler®

Spiriva® Respimat®

Respimat®

Incruse®

Ellipta®

Search for other inhalers

Explore the full list